Trial Profile
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 25 May 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 25 May 2023 Status changed from completed to discontinued (terminated at pre-planned futility analysis).
- 28 Feb 2023 Status changed from active, no longer recruiting to completed.
- 09 Aug 2022 Results retrospectively analyzing CT images and associated clinical metadata for patients enrolled on SWOG S0819, presented at the 2022 World Conference on Lung Cancer